Bharat Biotech, GSK join hands to develop vaccine for severe diarrhoea

Bharat Biotech and GSK plc have partnered to develop a vaccine for Shigellosis, a severe bacterial diarrhea. The altSonflex1-2-3 vaccine candidate, developed by GSK, will be further developed by Bharat Biotech, including Phase 3 trials and manufacturing. This collaboration aims to address the urgent need for a Shigella vaccine due to rising antimicrobial resistance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JvfzKWV
via IFTTT